The efficacy and safety of RC88 in patients with ovarian cancer, …
Background: RC88 is a first-in-class, antibody-drug conjugate (ADC) targeting mesothelin (MSLN) with the payload of Monomethyl auristatin E. MSLN, a glycosylphosphatidylinositol-anchored …
Translation of the efficacy of antibody–drug conjugates from ...
RC88 is a novel anti‐mesothelin ADC consisting of a humanized anti‐mesothelin monoclonal antibody conjugated microtubule inhibitor, monomethyl auristatin E (MMAE). Mouse TGI data …
Preclinical safety profile of RC88-ADC：a novel mesothelin …
RC88-ADC is a novel ADC, targeting MSLN, and inhibits tumor growth significantly in mice xenograft models. We performed an 11-week repeated dose toxicity study of RC88-ADC via …
Background: RC88 is a first-in-class, antibody-drug conjugate (ADC) targeting mesothelin (MSLN) with the payload of Monomethyl auristatin E. MSLN, a glycosylphosphatidylinositol-anchored …
荣昌生物制药（烟台）股份有限公司_荣昌生物 - RemeGen
RC88 is a new type of mesothelin-targeting ADC and uses innovative bridging technology independently developed by RemeGen to connect antibodies and drugs. It includes MSLN …
FDA Grants Fast Track Designation to RC88 in Ovarian Cancer
Jan 12, 2024 · The FDA has granted a fast track designation (FTD) to RC88 for the treatment of platinum-resistant ovarian, fallopian tube, and peritoneal cancers. RC88 is a novel mesothelin …
RC88 is a novel anti- mesothelin ADC consisting of a human-ized anti- mesothelin monoclonal antibody conjugated microtubule inhibitor, monomethyl auristatin E (MMAE). Mouse TGI data …
Translation of the efficacy of antibody-drug conjugates from ...
Three semimechanistic pharmacokinetic/pharmacodynamic (PK/PD) models, Simeoni, Jumbe, and Hybrid, were used for the efficacy translation of RC88 from preclinical to clinical. RC88 is …
Preclinical safety profile of RC88-ADC：a novel ... - ResearchGate
Nov 28, 2021 · RC88-ADC is a novel ADC, targeting MSLN, and inhibits tumor growth significantly in mice xenograft models. We performed an 11-week repeated dose toxicity study …
RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds …
Jan 12, 2024 · RC88 is a novel antibody drug conjugate (ADC) independently developed by RemeGen targeting mesothelin (MSLN). It uses the company's independently developed …
- Some results have been removed